Qing-dai powder promotes recovery of colitis by inhibiting inflammatory responses of colonic macrophages in dextran sulfate sodium-treated mice

Chinese Medicine (United Kingdom)

Volumn 10, Issue 1, 2015, Pages

  Xiao, Hai Tao ^a,b   Peng, Jiao ^c   Hu, Dong Dong ^a,d   Lin, Cheng Yuan ^a   Du, Bin ^a   Tsang, Siu Wai ^a   Lin, Ze si ^a,e   Zhang, Xiao Jun ^a,e   Lueng, Feng Ping ^a   Han, Quan Bin ^a   Bian, Zhao Xiang ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b GUIZHOU MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

^d SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^e GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CYCLOOXYGENASE 2; DEXTRAN SULFATE; DRINKING WATER; HERBACEOUS AGENT; I KAPPA B ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; QING DAI; SALAZOSULFAPYRIDINE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; C57BL 6 MOUSE; CELL NUCLEUS; COLITIS; COLON INJURY; COLORIMETRY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIARRHEA; DISEASE ACTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTRACELLULAR TRANSPORT; MACROPHAGE FUNCTION; MACROPHAGE MIGRATION; MALE; MONOCYTE CHEMOTACTIC PROTEIN 1 BLOOD LEVEL; MOUSE; NONHUMAN; POWDER; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TRANSPORT; RAW 264.7 CELL LINE; RECTUM HEMORRHAGE; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION; WESTERN BLOTTING;

EID: 84945916263     PISSN: None     EISSN: 17498546     Source Type: Journal    
DOI: 10.1186/s13020-015-0061-x     Document Type: Article

References (36)

1. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573-621.
2. Chow DK, Leong RW, Tsoi KK, Ng SS, Leung WK, Wu JC, Wong VW, Chan FK, Sung JJ. Long-term follow-up of ulcerative colitis in the Chinese population. Am J Gastroenterol. 2009;104:647-54.
3. Wang YF, Ouyang Q, Hu RW. Progression of inflammatory bowel disease in China. J Dig Dise. 2010;11:76-82.
4. Macdermott RP, Green JA. Refractory ulcerative colitis treatment. Gastroenterol Hepatol (N Y). 2007;3:64-9.
5. Nanda K, Moss AC. Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX((R)) mesalamine. Clin Pharmacol. 2012;4:41-50.
6. Inflammatory Bowel Disease Co-operation Group CSoG. Consensus on diagnosis and treatment standard of inflammatory bowel disease. Chin J Gastroenterol. 2012;12:763-81.
7. Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006;55:1255-62.
8. Kaser A, Zeissig S, Blumberg RS. Inflammatory Bowel Disease. Annu Rev Immunol. 2010;28:573-621.
9. Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390-407.
10. Saleh M, Trinchieri G. Innate immune mechanisms of colitis and colitisassociated colorectal cancer. Nat Rev Immunol. 2011;11:9-20.
11. Blumberg RS. Inflammation in the intestinal tract: pathogenesis and treatment. Dig Dis. 2009;27:455-64.
12. Velde AAT, van Kooyk Y, Braat H, Hommes DW, Dellemijn TAM, Slors JFM, van Deventer SJH, Vyth-Dreese FA. Increased expression of DC-SIGN + IL-12 + IL-18 + and CD83 + IL-12-IL-18-dendritic cell populations in the colonic mucosa of patients with Crohn's disease. Eur J Immunol. 2003;33:143-51.
13. Vuckovic S, Florin THJ, Khalil D, Zhang MF, Patel K, Hamilton I, Hart DNJ. CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases. Am J Gastroenterol. 2001;96:2946-56.
14. Yoshino T, Nakase H, Honzawa Y, Matsumura K, Yamamoto S, Takeda Y, Ueno S, Uza N, Masuda S, Inui K, Chiba T. Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis. Inflamm Bowel Dis. 2010;16:2022-33.
15. Zigmond E, Varol C, Farache J, Elmaliah E, Satpathy AT, Friedlander G, Mack M, Shpigel N, Boneca IG, Murphy KM, et al. Ly6C(hi) monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. Immunity. 2012;37:1076-90.
16. Steinbach EC, Plevy SE. The role of macrophages and dendritic cells in the initiation of inflammation in IBD. Inflamm Bowel Dis. 2014;20:166-75.
17. Ghia J-E, Galeazzi F, Ford DC, Hogaboam CM, Vallance BA, Collins S. Role of M-CSF-dependent macrophages in colitis is driven by the nature of the inflammatory stimulus. Am J Physiol Gastrointest Liver Physiol. 2008;294:G770-7.
18. Cheng Z, editor. Yi-Fang-Lei-Ju (reprint edition). Beijing: People's Medical Publishing House; 2006.
19. Du L, Liu R. The effect of Qing-dai San in treatment of colitis: 118 cases clinical study. Liaoning J Tradit Chin Med. 1998;25:356-7.
20. Xie Z, Li H, Du L. Clinical research progress of Qingdaisan enema for ulcerative colitis treatment. China Med Her. 2013;10:31-3.
21. Zou L, Liu Y, Wu Q, Xian Y, Zhou H, Du L. Effect of Qingdaisan on ulcerative colitis in rats. J China Med Univ. 2006;35:15-6.
22. Kim JK, Park GM. Indirubin-3-monoxime exhibits anti-inflammatory properties by down-regulating NF-kappaB and JNK signaling pathways in lipopolysaccharide-treated RAW264.7 cells. Inflamm Res. 2012;61:319-25.
23. Commission CP, editor. Chinese pharmacopoeia (1990), Part I. Beijing: People's Medical Publishing House; 1991.
24. Commission CP, editor. Chinese pharmacopoeia (2010), Part I. Beijing: Chemical Industry Publisher; 2011.
25. You SX, Liu SJ, Wu KD, Liu SH, Lin RC. The comparative study on FTIR fingerprint for alum and calcined alum. Chin J Pham Anal. 2011;31:1054-8.
26. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007;2:541-6.
27. Kim JM, Kang HW, Cha MY, Yoo D, Kim N, Kim IK, Ku J, Kim S, Ma SH, Jung HC, et al. Novel guggulsterone derivative GG-52 inhibits NF-kappaB signaling in intestinal epithelial cells and attenuates acute murine colitis. Lab Invest. 2010;90:1004-15.
28. Xiao HT, Lin C, Ho DHH, Peng J, Chen Y, Tsang SW, Wong M, Zhang XJ, Zhang M, Bian ZX. Inhibitory effect of the gallotannin corilagin on dextran sulfate sodium-induced murine ulcerative colitis. J Nat Prod. 2013;76:2120-5.
29. Chen X, Wu X, Zhou Q, Howard OM, Netea MG, Jj O. TNFR2 is critical for the stabilization of the CD4 + Foxp3 + regulatory T. cell phenotype in the inflammatory environment. J Immunol. 2013;190:1076-84.
30. Weigmann B, Tubbe I, Seidel D, Nicolaev A, Becker C, Neurath MF. Isolation and subsequent analysis of murine lamina propria mononuclear cells from colonic tissue. Nat Protoc. 2007;2:2307-11.
31. Fan H, Qi D, Yang M, Fang H, Liu K, Zhao F. In vitro and in vivo anti-inflammatory effects of 4-methoxy-5-hydroxycanthin-6-one, a natural alkaloid from Picrasma quassioides. Phytomedicine. 2013;20:319-23.
32. Adamec J, Jannasch A, Huang J, Hohman E, Fleet JC, Peacock M, Ferruzzi MG, Martin B, Weaver CM. Development and optimization of an LC-MS/MS-based method for simultaneous quantification of vitamin D2, vitamin D3, 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3. J Sep Sci. 2011;34:11-20.
33. Debnath T, Kim DH, Lim BO. Natural products as a source of anti-inflammatory agents associated with inflammatory bowel disease. Molecules. 2013;18:7253-70.
34. Moodley K, Mackraj I, Naidoo Y. Cardiovascular effects of Tulbaghia violacea Harv. (Alliaceae) root methanolic extract in Dahl salt-sensitive (DSS) rats. J Ethnopharmacol. 2013;146:225-31.
35. Bain CC, Scott CL, Uronen-Hansson H, Gudjonsson S, Jansson O, Grip O, Guilliams M, Malissen B, Agace WW, Mowat AM. Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol. 2013;6:498-510.
36. Lim WC, Hanauer SB. Controversies with aminosalicylates in inflammatory bowel disease. Rev Gastroenterol Disord. 2004;4:104-17.